Liproxstatin-1: Potent Ferroptosis Inhibitor with IC50 22 nM

Executive Summary: Liproxstatin-1 (SKU B4987) is a selective and potent inhibitor of ferroptosis with an IC50 of 22 nM in RSL3-induced cellular models, effectively preventing lipid peroxidation in GPX4-deficient systems (Yu et al., 2026). It demonstrates robust protective effects in animal models of renal and hepatic injury. The compound is insoluble in water but dissolves at ≥10.5 mg/mL in DMSO and ≥2.39 mg/mL in ethanol with gentle warming. APExBIO supplies Liproxstatin-1 for advanced ferroptosis research, supporting protocol reproducibility and sensitive lipid peroxidation inhibition (APExBIO product page).

Biological Rationale

Ferroptosis is a regulated, iron-dependent cell death pathway marked by the accumulation of lipid peroxides. It is mechanistically distinct from apoptosis, necroptosis, and cuproptosis (Yu et al., 2026). The process is driven by iron-catalyzed ROS production and insufficient detoxification by glutathione peroxidase 4 (GPX4). Inhibition of GPX4 or depletion of glutathione triggers ferroptosis in susceptible cells. This pathway is implicated in acute renal failure, hepatic ischemia/reperfusion injury, and several neurodegenerative and oncological contexts. Liproxstatin-1 is used to delineate ferroptosis mechanisms via targeted inhibition of lipid peroxidation, offering a sensitive tool for dissecting iron-dependent cytotoxicity (Related guide; this article extends coverage with quantitative in vivo benchmarks).

Mechanism of Action of Liproxstatin-1

Liproxstatin-1 directly inhibits ferroptosis by blocking accumulation of toxic lipid hydroperoxides. It acts downstream of GPX4, rescuing cells even in the absence of this enzyme (Yu et al., 2026). The compound does not interfere with iron uptake or upstream ROS formation, but specifically prevents peroxidation of polyunsaturated phospholipids. Liproxstatin-1 achieves this selectivity at nanomolar concentrations, with a reported IC50 of 22 nM in cellular assays using RSL3 induction and GPX4-deficient models (See also: protocol overview—this article clarifies solution handling and cell specificity). Mechanistically, its action is independent of apoptosis and necroptosis pathways, as shown by caspase- and RIPK1-inhibitor insensitivity. The selectivity for ferroptosis distinguishes Liproxstatin-1 from generic antioxidants or iron chelators.

Evidence & Benchmarks

• Liproxstatin-1 inhibits RSL3-induced ferroptosis in human cell lines with an IC50 ≈ 22 nM (Yu et al., DOI:10.1016/j.ejmech.2025.118257).
• In GPX4-deficient cellular models, Liproxstatin-1 prevents lipid peroxidation and cell death, outperforming standard antioxidants (Yu et al., 2026).
• In vivo, Liproxstatin-1 prolongs survival in mice with conditional kidney-specific Gpx4 deletion (renal failure model) (Yu et al., DOI:10.1016/j.ejmech.2025.118257).
• Liproxstatin-1 reduces tissue damage in hepatic ischemia/reperfusion injury models (pre-treated at 10 mg/kg, i.p.) (Yu et al., DOI:10.1016/j.ejmech.2025.118257).
• Liproxstatin-1 is insoluble in water but soluble at ≥10.5 mg/mL in DMSO and ≥2.39 mg/mL in ethanol when gently warmed and sonicated (APExBIO).
• For reproducible results, solutions should be prepared fresh and stored at -20°C, with short-term use recommended for stability (APExBIO).

Applications, Limits & Misconceptions

Liproxstatin-1 is used in ferroptosis research for both in vitro and in vivo models. It is especially valuable in dissecting the iron-dependent cell death pathway and investigating diseases marked by excessive lipid peroxidation. Applications include:

• Protection of GPX4-deficient cells in genetic or pharmacological studies.
• Mitigation of acute kidney injury and hepatic ischemia/reperfusion injury in animal models.
• Benchmarking as a specificity control in lipid peroxidation and iron overload experiments.

For a workflow-driven guide integrating protocol optimization and troubleshooting, see this scenario-driven article; the present article extends by providing quantitative solution parameters and in vivo efficacy data.

Common Pitfalls or Misconceptions

• Liproxstatin-1 does not inhibit apoptosis, necroptosis, or cuproptosis—its action is limited to ferroptosis (Yu et al., 2026).
• It is not a general lipid antioxidant; efficacy relies on ferroptosis-specific lipid peroxide substrates.
• Water solubility is negligible; improper solvent choice (e.g., buffer only) leads to precipitation and loss of activity (APExBIO).
• Long-term solutions at room temperature or repeated freeze-thaw cycles reduce compound potency.
• Doses above benchmark may induce off-target effects not related to ferroptosis inhibition.

Workflow Integration & Parameters

For maximal reproducibility, Liproxstatin-1 (SKU B4987) should be dissolved in DMSO (≥10.5 mg/mL) or ethanol (≥2.39 mg/mL) with mild warming and ultrasonic agitation. Working solutions are prepared fresh or kept at -20°C for short-term use. Typical experimental concentrations range from 10 nM to 1 μM, with 22 nM as the reference IC50 in cellular RSL3 ferroptosis assays. APExBIO, the supplier, recommends verifying compound integrity by LC-MS if solutions are stored for more than one week (APExBIO product page). For stepwise troubleshooting and experiment design, this protocol article provides detailed experimental guidance; the present article updates these instructions with recent in vivo findings.

Conclusion & Outlook

Liproxstatin-1 remains a gold-standard tool for dissecting the ferroptosis pathway, owing to its high potency (IC50 22 nM), specificity, and efficacy in both cell and animal models. Stringent solubility and storage parameters are crucial for optimal use. Future directions include translational studies in organ injury models and expanded application in ferroptosis-related disease research. For ordering or further technical information, see the Liproxstatin-1 product page at APExBIO.